SCHEMBL1930123

SCHEMBL1930123

CCOC(=O)N1CCC(N2CCC(N3C(=O)N[C@H]4CCCC[C@@H]43)CC2)CC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 8/20 0.64
OPRM1 P35372 7/20 0.64
OPRK1 P41145 3/20 0.58
CHRM1 P11229 3/20 0.53
MAPK1 P28482 1/20 0.50
CHRM2 P08172 2/20 0.49
CHRM4 P08173 2/20 0.49
CHRM5 P08912 1/20 0.49
CHRM3 P20309 1/20 0.49
OPRD1 P41143 1/20 0.49
TP53 P04637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
GAA P10253 1/20 0.45
ALOX12 P18054 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
THRB P10828 1/20 0.44
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1930080 1.00 OPRL1 (0.64) OPRL1OPRM1OPRK1CHRM1MAPK1
SCHEMBL1930019 1.00 OPRL1 (0.64) OPRL1OPRM1OPRK1CHRM1MAPK1
SCHEMBL12532093 1.00 OPRL1 (0.64) OPRL1OPRM1OPRK1CHRM1MAPK1
SCHEMBL12532059 1.00 OPRL1 (0.64) OPRL1OPRM1OPRK1CHRM1MAPK1
SCHEMBL1930233 1.00 OPRL1 (0.64) OPRL1OPRM1OPRK1CHRM1MAPK1
SCHEMBL1929240 0.93 OPRL1 (0.57) OPRL1OPRM1OPRK1CHRM1MAPK1
SCHEMBL1929604 0.93 OPRL1 (0.57) OPRL1OPRM1OPRK1CHRM1MAPK1
SCHEMBL12532119 0.93 OPRL1 (0.57) OPRL1OPRM1OPRK1CHRM1MAPK1
SCHEMBL1929422 0.93 OPRL1 (0.57) OPRL1OPRM1OPRK1CHRM1MAPK1
SCHEMBL1930009 0.93 OPRL1 (0.57) OPRL1OPRM1OPRK1CHRM1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070287695-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-12-13 US claimed
US-7956069-B2 Compounds ASTRAZENECA AB (SE) 2011-06-07 US disclosed
US-7956069-B2 Compounds ASTRAZENECA AB (SE) 2011-06-07 US disclosed
US-7956069-B2 Compounds ASTRAZENECA AB (SE) 2011-06-07 US disclosed
US-20070287695-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-12-13 US disclosed
US-20070287695-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-12-13 US disclosed
US-20070287695-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287695-A1 Novel Compounds OPRM1, OPRL1, OPRK1 OPRL1 2/4885OPRM1 1/4885OPRK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.